Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China

• Published in: BMC infectious diseases Vol. 24; no. 1; pp. 1141 - 10
• Main Authors: Ye, Li, Yang, Ye, Zhang, Xuewu, Wang, Lu, Zhu, Li, Li, Xia, Zhou, Yile, Zheng, Xiaolong, Zhou, Xinping, Ren, Yanling, Ma, Liya, Xu, Gaixiang, Yang, Chunmei, Wang, Huafeng, Zhou, De, Yang, Min, Ye, Xingnong, Wei, Juying, Yu, Wenjuan, Qian, Jiejing, Lou, Yinjun, Xie, Wanzhuo, Huang, Jian, Meng, Haitao, Jin, Jie, Tong, Hongyan
• Format: Journal Article
• Language: English
• Published: England BMC 11.10.2024
• Subjects: Adult; Aged; Antibodies, Viral - blood; China - epidemiology; COVID-19; COVID-19 - blood; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - mortality; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Female; Hematologic malignancy; Hematologic Neoplasms - complications; Hematologic Neoplasms - immunology; Humans; Immunoglobulin G - blood; Male; Middle Aged; Omicron; Prognosis; Retrospective Studies; SARS-CoV-2 - immunology; Vaccination; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - immunology; China; COVID-19; Prognosis; Omicron; Hematologic malignancy
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-024-10063-2

The essence of this scholarly work was to carefully outline the key factors intensifying the virulence and protracted contagion of COVID-19, particularly among individuals afflicted with hematologic malignancies (HM), in an epoch predominantly governed by the Omicron variant. Adults with HM diagnosed with COVID-19 from November 2022 to February 2023 were monitored in this retrospective study. Patient blood samples yielded biochemical data, and COVID-19 was confirmed through RNA or antigen testing. The factors affecting severity and infection duration were examined using both univariate and multivariate logistic regression analyses. For calculating the overall survival probabilities, the Kaplan-Meier product limit approach was employed. In the examined cohort, 133 individuals diagnosed with HM and concomitantly infected with COVID-19 were scrutinized. Of the participants, 29.3% (39 patients) were classified as Severe/Critical, while the other 70.7% (94 patients) were categorized as Non-severe. A significant difference was observed in vaccination status: 61.7% of patients in the Non-severe group had received at least a two-dose vaccine regimen, whereas 61.5% of the Severe/Critical group had either minimal or only one dose of vaccination. The data analysis revealed that elevated C-reactive protein levels (≥ 100 mg/L) significantly raised the risk of severe/critical conditions in HM patients with COVID-19, as determined by advanced multivariate logistic regression. The odds ratio was 3.415 with a 95% confidence interval of 1.294-9.012 (p = 0.013). Patients who continued to have positive nucleic acid tests and ongoing symptoms beyond 30 days were categorized as having a persistent infection, whereas those who achieved infection control within this timeframe were categorized as having infection recovery. Of the HM cohort, 11 did not survive beyond 30 days after diagnosis. The results from a competing risk model revealed that increased interleukin-6 levels (HR: 2.626, 95% CI: 1.361-5.075; p = 0.004) was significantly associated with persistent infection. Conversely, receiving more than two vaccine doses (HR: 0.366, 95% CI: 0.158-0.846; p = 0.019), and having high IgG levels (≥ 1000 mg/dl) (HR: 0.364, 95% CI: 0.167-0.791; p = 0.011), were associated with infection recovery. There was a notable disparity in survival rates between patients with persistent infections and infection recovery, with those in the non-persistent group demonstrating superior survival outcomes (P < 0.001). In conclusion, the study determined that HM patients with COVID-19 and increased C-reactive protein levels had a higher likelihood of severe health outcomes. Persistent infection tended to be more prevalent in those with vaccine dosages (< 2 doses), lower IgG levels, and higher interleukin-6 levels.